Inhibrx Executives Buy 30,000 Options in Surge of Insider Confidence, Betting on 25% Upside Before 2027 Vesting Window Opened

Insider Buying Signals: Douglas Locks in a New Batch of Options

On June 3, 2026, former director Forsyth Douglas purchased a 10,000‑share block of stock options with a grant date of the same day and a full exercisability date set for June 3, 2027. The transaction was filed as a Form 4/A, indicating a derivative transaction rather than a direct purchase of common shares. Although the options are currently “at‑no‑cost,” the grant itself is a bullish cue: Douglas is effectively betting on future upside, and the exercise price is likely to be close to the current market price of $109.35, giving him a potential upside of up to 25 % before the options vest in a year. For investors, this move suggests that insiders remain confident in Inhibrx’s growth trajectory and believe the company is undervalued relative to its 52‑week high of $155.29.

Broader Insider Activity Signals Momentum

In the same filing window, three other senior executives—Vuori Kristiina MD, Kimberly Manhard, and Jon Faiz Kayyem—each also acquired 10,000 options. The cluster of option purchases at a single filing date is unusual and points to a coordinated confidence in the company’s near‑term prospects. While option activity does not equal cash flow, it is often used by insiders to align their interests with shareholders, as the options’ value is tied directly to share price performance. The timing of these purchases coincides with a modest 0.07 % weekly price gain and a 7.76 % monthly increase, suggesting that the market is already reacting to positive news, possibly related to clinical pipeline developments or partnership announcements that are still pending public disclosure.

What This Means for Investors

1. Alignment of Interests – The simultaneous option buys by multiple executives reinforce a narrative that the leadership team is optimistic about the company’s valuation. Investors may view this as a signal that insiders expect a rally in the coming months.
2. Potential Share‑Price Upside – If Inhibrx’s stock continues its upward trajectory, the options will likely become valuable before they vest. This can create a positive feedback loop, where insider confidence fuels market enthusiasm, driving the price higher.
3. Risk of Lock‑in Periods – Options usually vest over a multi‑year schedule, so the immediate impact on liquidity is limited. However, if insiders exercise early, it could add pressure on the price if the supply increases.

Forsyth Douglas: A Profile of Consistent Commitment

Douglas has a long history of purchasing stock options and shares in Inhibrx, dating back to May 2025. Over the past 18 months he has acquired:

• 15 000 options in May 2025 (grant date same as purchase)
• 15 000 options in June 2026 (grant date same as purchase)
• 15 000 options in September 2026 (grant date same as purchase)
• 2 500 shares in September 2026 at $114.65 each

This pattern shows a steady accumulation of equity without significant divestitures, indicating a belief in long‑term value creation rather than short‑term speculation. Unlike some insiders who mix sales and purchases, Douglas’s activity is largely buy‑heavy, suggesting that he expects the company’s fundamentals to improve over the next two to three years.

Conclusion

The recent Form 4/A filings, coupled with a broader wave of option purchases by senior executives, paint a picture of an insider group that is bullish on Inhibrx Biosciences. While options do not immediately alter share supply, they signal confidence and set the stage for potential future upside. For investors, the key takeaway is that the leadership’s recent moves could presage a period of accelerated growth, but they should remain vigilant for any shifts in the company’s clinical pipeline or regulatory environment that could alter this optimistic outlook.